| Objectives By setting up animal model of micro-implant anchorage of bandicoot withdiabetes, the experimenter watches the effect of Metformin Intervention Therapy onmicro-implant anchorage and discusses the boosting effect of melbinum in curingdiabetes and recovering bones. The experimenter hopes to provide new thoughts andexperimental evidence for clinical diabetic patients.Methods Purchase of30Wistar rats,6~8weeks of age, male. Randomly divided into3groups: normal control group, diabetes group, diabetes with metformin group, therebeing10in each. Feed the first group with ordinary fodder and the rest two groups withfatty fodder with streptozotocin (STZ solution40mg/kg). After4weeks, conduct theanimal model of male rats with diabetes. After modeling, plant1.6mm micro-implant inleft tibia of them all. The next day since then, lave rats in control group and diabeticgroups with0.9%physiological saline. Each one has2ml. Cure rats in the third groupwith melbinum, dosage0.2g/(kg·d);2weeks after plantation, increase the weight ofmicro-implant60g. Kill the former14d,13d,4d,3d and mark them with tetracyclinehydrochloride and calcein by hypodermic injection. Check bone substance density of ratswhen they are implanted, loaded and before being killed. Kill them all12weeks afterimplantation and check their serologic indexes. Make undecalcified bone tissue sliceswith micro-implant, observe and calculate bone contact ratio and bone mineral appositionrate. Handle experiment statistics with SPSS17.0.Results1As watched in diabetic animal model, the rats have the identical symptoms ofgluttony, crapulence of water, diuresis and skinniness; fasting blood-glucose＞16.7mmol/L. During the experiment,2rats in diabetic group are diagnosed with cataract.The diabetes with melbinum group improves its diabetic symptoms greatly.2Micro-implant displacement: micro-implant displacement happens in all the3groups.Displacement in diabetic group is greater than diabetes with melbinum group andsymptoms in both of them are greater than normal control group. The contrast ismeaningful in statistics(P<0.01).3Serological detection: Compared with normal controlgroup, diabetic fasting glucose, fasting insulin and serum total cholesterol, serumtriglycerides were significantly increased, ISI lower, the difference was statistically significant (P<0.05). Compared with diabetic group, glucose, TC, TG of rats in diabeteswith metformin group becomes significantly lower (P<0.05). ISI becomes muchhigher(P<0.05), while fasting insulin decreases significantly (P<0.05). Contrast betweenthe other two groups is meaningless(P＞0.05).4Changes in bone density: As experimentgoes on, bone densities of rats in diabetic, diabetic with metformin groups decrease invarying degrees. But bone densities of rats in diabetic with metformin group increaseafter therapy. There are significant statistical differences (P <0.01) in tibia of rats in thethree groups.5Micro-implant osseointegration rates comparison: Bone contact ratio ofrats in normal control group is the highest. The ratio of rats in diabetes with metformingroup is higher than rats in diabetic group. Pairwise comparisons among the three groupswas statistically significant (P<0.05). Bone mineral apposition rate is higher in the withdiabetes with metformin group than that of diabetic group(P<0.05).6Histologicalobservation of fluorescence: double fluorescent marked band appear in all the3groups.Fluorescence mainly focuses on bone’s micro-implant interface and bone trabecula.Under fluorescence microscope, bone’s formation of diabetes with metformin group ishigher in organization level than that of control group. It also has more double markedlines. It has clear tetracycline double marked line with boarder interval. Its mineralizationappositional rate accelerates(P<0.05). Diabetic group double marked lines decrease andits interval narrows.7Peri-implant bone tissue micro-morphological: At12weeks, thecontrol group slightly thick lamellar bone implant surfaces, mainly for mature lamellarbone, good continuity. A large number of osteoblasts, osteoclasts occasionally. Newlyformed bone plate diabetic group of small, poor continuity, osteoblasts sparse. Micro-implant and bone tissue have more non-contact area, and although some areasosseointegration occurred, but the maturity is not high. The bone plate of diabetes withmetformin group is relatively board and well-connected. The bone tissue surroundingmicro-implantation is intense and its maturity is higher.Conclusion1With fat-rich fodder and streptozotocin (STZ solution40mg/kg), we canset up type II diabetic animal model.2Melbinum can control blood sugar, regulate bonemetabolism and improve the quality of bone knitting. |
PDF Full Text Request